A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)
S
Sashidhar Sagi, MD
Primary Investigator
Overview
This study is designed to evaluate the long-term efficacy and safety of mirikizumab inwith moderately to severely active ulcerative colitis (UC).
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Ulcerative Colitis
-
Age: Between 18 Years - 80 Years
-
Gender: All
- Inclusion Criteria
- Participants from Study AMAC (NCT02589665) or AMBG (NCT03524092) who have had atudy drug administration and have not had early termination of studydrug.
- Female participants must agree to contraception requirements.
- Exclusion Criteria
- Participants must not have developed a new condition, including cancer in the
originator study.
- Participants must not have any important infections including, but not limitedhepatitis B, hepatitis C, HIV/AIDS, and active tuberculosis (TB) duringher originator study
- Participants may not have received surgery for UC in the originator study or arekely to require surgery for treatment of UC during the study.
- Participants must not have developed adenomatous polyps during the originatorudy that have not been removed prior to the start of this study.
Updated on
03 May 2024.
Study ID: 16596
Please visit our main page to search for other studies you may be interested in.
If you need help finding a study or have any questions, please contact us at inhealth@iu.edu
